Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (600276.SH) has announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd., have received official approval notices from the National Medical Products Administration for clinical trials involving the injection SHR-A2009 and the Adebrelimab injection. The clinical trials are scheduled to commence in the near future.

In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the applications for the injection SHR-A2009 and the Adebrelimab injection, which were accepted on May 13, 2026, have been reviewed and found to meet the necessary requirements for drug registration. The approval permits the initiation of Phase II clinical trials for the combination of the injection SHR-A2009 with Adebrelimab, or with a third-generation EGFR TKI, for the treatment of patients with non-small cell lung cancer.